<SEC-DOCUMENT>0001140361-24-040872.txt : 20240911
<SEC-HEADER>0001140361-24-040872.hdr.sgml : 20240911
<ACCEPTANCE-DATETIME>20240911210024
ACCESSION NUMBER:		0001140361-24-040872
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240909
FILED AS OF DATE:		20240911
DATE AS OF CHANGE:		20240911

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Guiheen Lawrence P.
		CENTRAL INDEX KEY:			0001554353
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		241293744

	MAIL ADDRESS:	
		STREET 1:		65 COMMERCE WAY
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-09-09</periodOfReport>

    <issuer>
        <issuerCik>0001368514</issuerCik>
        <issuerName>ADMA BIOLOGICS, INC.</issuerName>
        <issuerTradingSymbol>ADMA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001554353</rptOwnerCik>
            <rptOwnerName>Guiheen Lawrence P.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADMA BIOLOGICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>465 STATE ROUTE 17</rptOwnerStreet2>
            <rptOwnerCity>RAMSEY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07446</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-09-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>10.8</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>162941</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-09-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>18.4654</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>153941</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>10.8</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-09-09</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9000</value>
                    <footnoteId id="F5"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>10.8</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2025-01-30</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>9000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $18.465 to $18.47. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</footnote>
        <footnote id="F2">Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (ii) 141,921 shares of common stock owned by the Reporting Person.</footnote>
        <footnote id="F3">These shares are owned by the Guiheen Trust, of which the Reporting Person serves as a joint trustee.</footnote>
        <footnote id="F4">These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.</footnote>
        <footnote id="F5">The Reporting Person is exercising these options due, in part, to their near-term expiration date.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Lawrence P. Guiheen, by Adam S. Grossman as Attorney-in-fact</signatureName>
        <signatureDate>2024-09-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ef20035739_ex24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.8.1.5246
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial; font-size: 9pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none; font-size: 10pt; font-family: 'Times New Roman';">
  <div>
    <div style="text-align: right; font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';">Exhibit 24</div>
  </div>
  <div> <font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
    </font></div>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">LIMITED POWER OF ATTORNEY</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FOR SECTION 16(a) REPORTING</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Adam S. Grossman, President and Chief Executive
      Officer, and Michael A. Goldstein, Senior Director, General Counsel, of ADMA Biologics, Inc. (the &#8220;Company&#8221;), and each of them, as the undersigned&#8217;s true and lawful attorney-in-fact (the &#8220;Attorney-in Fact&#8221;), with full power of substitution and
      resubstitution, with the power to act alone for the undersigned and in the undersigned&#8217;s name, place and stead, in any and all capacities to:</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;prepare, execute and submit to the Securities and Exchange Commission (&#8220;SEC&#8221;), any national securities exchange and the Company any and all
        reports (including any amendment thereto) of the undersigned required or considered advisable under Section 16(a) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), and the rules and regulations thereunder, with respect to the equity
        securities of the Company, including Form&#160;3 (Initial Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes in Beneficial Ownership), and Form 5 (Annual Statement of Changes in Beneficial Ownership); and</font></div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;seek or obtain, as the undersigned&#8217;s representative and on the undersigned&#8217;s behalf, information regarding transactions in the Company&#8217;s equity
        securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.</font></div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned acknowledges that:</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Limited Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act at his discretion on information provided to such
        Attorney-in-Fact without independent verification of such information;</font></div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any documents prepared and/or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in
        such form and will contain such information as the Attorney-in-Fact, in his discretion, deems necessary or desirable;</font></div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned&#8217;s responsibility to comply with the requirements of
        Section 16 of the Exchange Act, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and</font></div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned&#8217;s obligations under
        Section 16 of the Exchange Act, including, without, limitation, the reporting requirements under Section 16(a) of the Exchange Act.</font></div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or
      convenient to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his substitute or substitutes, shall
      lawfully do or cause to be done by authority of this Limited Power of Attorney.</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms&#160;3, 4 or 5 with respect
      to the undersigned&#8217;s holdings of and transactions in equity securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Limited Power of Attorney shall be governed by and construed in accordance the laws of the State of Delaware without regard to the laws that
      might otherwise govern under applicable principles of conflicts of laws thereof.</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of March 28, 2024.</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">
      <table cellspacing="0" cellpadding="0" border="0" id="z42d665ddcf18444aa5374409615aae98" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 30%;"><br>
            </td>
            <td style="width: 10%;">Signature:</td>
            <td style="width: 60%;"><u>/s/ Lawrence P. Guiheen</u></td>
          </tr>
          <tr>
            <td style="width: 30%;"><br>
            </td>
            <td style="width: 10%;">Print Name:</td>
            <td style="width: 60%;">Lawrence P. Guiheen</td>
          </tr>

      </table>
      <br>
      <br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  <font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
